These results indicate that there is a consistent relationship between GLP-1 receptor agonist use and a decrease in hazard of multiple myeloma among individuals with type 2 diabetes mellitus, including in those with poor glucose control and those with obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.